Journal of Liver Cancer

Original Article

PNPLA3 I148M is unrelated to HCC occurrence but associates with poorer tumor differentiation in Korean MASLD: a prospective cohort of 562 patients: Jaejun Lee, Dong Yeop Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Pil Soo Sung; J Liver Cancer. 2026;26(1):147-156. Published online December 4, 2025; DOI: https://doi.org/10.17998/jlc.2025.11.16

1,033 Views
60 Downloads

Abstract PDF Supplementary Material: Backgrounds/Aims
The patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M variant has been implicated in metabolic dysfunction-associated steatotic liver disease (MASLD), but its role in hepatocellular carcinoma (HCC) development is unclear. This study examines the association between the PNPLA3 I148M variant and HCC occurrence.
Methods
A total of 562 MASLD patients, with and without HCC, were prospectively and consecutively enrolled at two universityaffiliated hospital between June 2024 and June 2025. Genomic DNA was extracted from buccal swabs or liver biopsy samples, and single nucleotide polymorphism genotyping was performed to determine the rs738409 genotype at codon 148 of PNPLA3. The histological grade of HCC was assessed using the Edmondson-Steiner (ES) grading system in patients who underwent core-needle liver biopsy.
Results
Among 474 non-HCC patients, the GG genotype was found in 39.9%, GC in 37.1%, and CC in 23.0%. In 88 HCC patients, these frequencies were 45.5%, 36.4%, and 18.2%, respectively. No significant differences in GG genotype distribution were observed between HCC and non-HCC groups (P=0.509), nor in subgroups by sex, age, obesity status, cirrhosis status, fibrosis-4 index, or liver stiffness measurement. However, among HCC patients with histological grading, the GG genotype was significantly associated with higher ES grades (P=0.0076).
Conclusions
The PNPLA3 I148M GG genotype was not significantly associated with increased HCC occurrence in Korean MASLD patients within the present cohort. Although the GG genotype is known to play a role in development and progression of MASLD, further studies are warranted to clarify its contribution to tumor initiation and dedifferentiation.

Review Articles

Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide: Do Young Kim; J Liver Cancer. 2024;24(1):62-70. Published online March 25, 2024; DOI: https://doi.org/10.17998/jlc.2024.03.13

45,354 Views
1,177 Downloads
131 Citations

Abstract PDF

Approximately 80% of hepatocellular carcinoma (HCC) cases arise in sub-Saharan Africa and Eastern Asia, following a similarly high prevalence of chronic hepatitis B virus (HBV) carriers in these regions. The etiology and epidemiology of HCC have recently changed worldwide. Although HBV infection is the main contributor to HCC development, a slow but continuous decline in HBV infection rates has been reported since 1990. Owing to the widespread use of direct-acting antivirals, the incidence of hepatitis C virus-related HCC has remarkably decreased in Japan and European countries. In Korea, Taiwan, and Singapore, the incidence of HBV-related HCC has significantly decreased owing to vaccination against HBV. Globally, while HBV accounted for more than half of HCCs in 1990, this had decreased to 42% in 2019. In contrast, the proportion of patients with alcoholic- and nonalcoholic steatohepatitis (NASH) increased from 13% to 18% and from 5% to 6%, respectively. NASH-related HCC has characteristics that differ from those of virus-associated HCC. Compared with other etiologies, patients with NASHassociated HCC are older, have a higher body mass index, and have higher rates of type 2 diabetes mellitus, hypertension, hyperlipidemia, and cardiovascular disease. Nonalcoholic fatty liver disease (NAFLD)-associated HCC is also known to develop in the absence of cirrhosis, unlike alcohol-related and autoimmune liver diseases. Because patients with NAFLD usually have diabetes or obesity, surveying this population is challenging. Optimal selection of the target population and surveillance tools among patients with NAFLD needs to be determined.

Citations

Citations to this article as recorded by

Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications
Maciej Gonciarz, Benita Wiatrak, Iga Lombard, Łukasz Konecki, Joanna Sarbinowska
Journal of Pineal Research.2026;[Epub] CrossRef
Functional imaging: a game changer for biomarker discovery and treatment response among patients with hepatocellular carcinoma
Shadi Afyouni, Ghazal Zandieh, Timothy M. Pawlik, Ihab R. Kamel
Expert Review of Gastroenterology & Hepatology.2026; 20(1): 29. CrossRef
Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: A nationwide target trial emulation study
Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
Annals of Hepatology.2026; 31(1): 102175. CrossRef
Efficacy and Safety of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Muhammad A.B. Naeem, Muhammad R. Paracha, Ahmad Noor, Muhammad H.A. Khalid, Hafiza K. Shahid, Maaz Khan, Moeaza R. Rizvi, Javeeria Arshad, Talha Abbas, Azeem Saeed, Hamza Ashraf, Minahil Ali, Mishal Asif, Aanusha Ghouri
American Journal of Clinical Oncology.2026; 49(4): 196. CrossRef
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2026; 32(1): 368. CrossRef
BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of 225Ac-GPC3 (BAY 3547926) in Patients with Advanced Hepatocellular Carcinoma
Jorrit Tjeertes, Miroslav Dostalek, Charles Glaus, Vinita Gupta, Daneng Li, Antje Nestler, Vasiliki Pelekanou, Joerg Pinkert, Ida Ratih, Eric Smith, Shyamal Subramanyam, Arndt Vogel, Katrina Walker, Andrea Wilson Woods, Stefan Zimmermann, Henrik Junger
Journal of Nuclear Medicine.2026; 67(3): 360. CrossRef
Gut microbiota's role in NAFLD- and HBV/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications
Gursimran Singh, Shazia Ansari, Satyam Yadav, Khadga Raj Aran
Microbial Pathogenesis.2026; 211: 108273. CrossRef
The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study
Tae Seop Lim, Seok Jong Chung, Jimin Jeon, Ja Kyung Kim, Jinkwon Kim
Gut and Liver.2026; 20(1): 107. CrossRef
Efficient sustainable nanocarrier based on graphene oxide functionalized with antitumor methotrexate for cancer therapy
Mohamed Shemis, Hesham Moustafa, Fatma H Salman, Gehan Safwat, Mona Moharib, Samah Mamdouh
Next Research.2026; 5: 101368. CrossRef
Nuclear miR-3920 expression in hepatocellular carcinoma is associated with stemness marker expression and poorer prognosis
Hyunjin Park, Seunghye Kim, Hyejung Lee, Hee Young Na, Jeong Eun Yoo, Haeryoung Kim
Digestive and Liver Disease.2026; 58(3): 390. CrossRef
Matrix Metalloproteinases in Hepatocellular Carcinoma: Mechanistic Roles and Emerging Inhibitory Strategies for Therapeutic Intervention
Alexandra M. Dimesa, Mathew A. Coban, Alireza Shoari
Cancers.2026; 18(2): 288. CrossRef
Protein tyrosine phosphatase 1B in solid tumors: Unraveling its clinical significance
José Esparza-López, Alejandro Aranda-Gutierrez, Elizabeth Escobar-Arriaga, Citlali Frayde-Aguilar, M. Andrea Mac Donald Jamarillo, Eucario Leon-Rodriguez, María de Jesús Ibarra-Sánchez
Revista de Investigación Clínica.2026; 78(1): 100035. CrossRef
Comprehensive Evaluation and Validation Reveal Mitochondrial Solute Carrier SLC25A3 as a Novel Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma
Beibei Bie, Libing Liu, Furong Wang, Xianing Meng, Mengdi Wu, Jin Sun
Journal of Hepatocellular Carcinoma.2026; Volume 13: 1. CrossRef
Antioxidant and Molecular Insights into the Anticancer Potential of Argemone Mexicana L. Seed Extract on HepG2 Cell Line
Aishwarya R. Kurdekar, A. M. Krupanidhi, S. M. Pratiksha, Prakash Dabadi
Cell and Tissue Biology.2026; 20(2): 113. CrossRef
Knowledge on modes of hepatitis B transmission and the practice of family screening and vaccination among patients with chronic hepatitis B infection at a tertiary center in Ethiopia
Sewale Anagaw, Hailemichael Desalegn, Arsema Goytom, Henok Fisseha, Kinfe Woldu, Bizatu Mengistie
BMC Gastroenterology.2026;[Epub] CrossRef
Exploring the Role of Extracellular Vesicles in Pancreatic and Hepatobiliary Cancers: Advances Through Artificial Intelligence
Eleni Myrto Trifylli, Athanasios Angelakis, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Michalis V. Karamouzis, Spilios Manolakopoulos, Melanie Deutsch
International Journal of Molecular Sciences.2026; 27(3): 1524. CrossRef
Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia
Yasuto Takeuchi, Ryosuke Tateishi, Shuntaro Obi, Motoyuki Otsuka, Hitoshi Mochizuki, Amarsanaa Jazag, Osamu Yokosuka, Sadahisa Ogasawara, Naoya Kanogawa, Erdenebayar Gonchig, Yuki Matsushita, Murat Kekilli, Gulden Bilican, Yoon Jun Kim, Moon Haeng Hur, Mi
Hepatology International.2026; 20(2): 373. CrossRef
E-cigarette switching, smoking cessation, and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study in South Korea
Byeong Geun Song, Myeongcheol Lee, Juhee Cho, Geum-Youn Gwak, Danbee Kang, Dong Hyun Sinn
Preventive Medicine.2026; 205: 108530. CrossRef
H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression
Masahiro Yamane, Yoshimitsu Akiyama, Shu Shimada, Shuichi Watanabe, Megumi Hatano, Shu Tsukihara, Suguru Miyazawa, Hanako Tamura, Atsushi Nara, Keita Kodera, Kohei Okazaki, Yoshiaki Tanji, Yosuke Igarashi, Atsushi Kamachi, Kentaro Umemura, Koya Yasukawa,
JHEP Reports.2026; 8(5): 101786. CrossRef
Comparison between mRECIST, EASL, and qEASL methods with AFP as tumor response parameters after local chemotherapy in patients with intermediate hepatocellular carcinoma
I G. WIJAYA, Nikmatia LATIEF, Rafikah RAUF, Firdaus HAMID, Bachtiar MURTALA, Luthfi PAREWANGI
Gazzetta Medica Italiana Archivio per le Scienze Mediche.2026;[Epub] CrossRef
Multi-omics biomarker detection in Diethylnitrosamine (DENA) induced hepatocellular carcinoma
Obaid Afzal, Pavan Goud, Kavita Goyal, Ali Altharawi, Mubarak A. Alamri, Manal A. Alossaimi, Abdulmalik S.A. Altamimi, Surya Nath Pandey
Clinica Chimica Acta.2026; 587: 120937. CrossRef
Serum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma
Muhammad Taher, Muhamad Aqil Ikram Muhamad Asri, Nur Damia Abdul Rahman, Nur Eleisha Zamzuri, Nur Syazwani Mohammad Farizal, Junaidi Khotib, Deny Susanti, Nurul Athirah Hasdan, Muhammad Salahuddin Haris, Rita Rakhmawati
Journal of the Egyptian National Cancer Institute.2026;[Epub] CrossRef
Response: Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC
Jung Sun Kim, Thomas Yau, Hong Jae Chon
Liver International.2026;[Epub] CrossRef
Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances
Saeed Khavari Khorasani, Siavash Boroumandi, Ali Darzi, Mahla Shokouhfar, Pedram Abdali, Pooya Eini, Ahmad Ghorbani Vanan, Nastaran Bahrami
Clinical and Experimental Medicine.2026;[Epub] CrossRef
Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation
Siyao Wang, Yang Wu, Miao Yuan, Jing Zheng, Chaoran Wang, Jiarong Wang, Yifan Zheng, Qiaoyun Yang, Mengran Xu, Baiqi Wang
International Journal of Nanomedicine.2026; Volume 21: 1. CrossRef
PNPLA3 I148M is unrelated to HCC occurrence but associates with poorer tumor differentiation in Korean MASLD: a prospective cohort of 562 patients
Jaejun Lee, Dong Yeop Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Pil Soo Sung
Journal of Liver Cancer.2026; 26(1): 147. CrossRef
A Narrative Review of the Therapeutic Effectiveness of Lenvatinib in Comparison With Immunotherapy for the Treatment of Non-Viral Advanced Hepatocellular Carcinoma
Pankaj Sonone , Sumit Goyal, Nilesh Lokeshwar, Shruti Dharmadhikari, Gaurav Puppalwar, Chintan Khandhedia, Amey Mane, Suyog Mehta
Cureus.2026;[Epub] CrossRef
Identification of a Calcium-Related Prognostic Signature and Validation of CACNA1B as a Driver of Metastasis in Hepatocellular Carcinoma
Yanling Chen, Yarong Ma, Guorui Zhao, Jianhao Li, Guizhen Zhang
Journal of Hepatocellular Carcinoma.2026; Volume 13: 1. CrossRef
Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib
Kyuyoung Han, Eun-Kyoung Jwa, Suhyeon Ha, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Seoon Kang, Hye Ok Kim, Hyunhee Kwon, Dong-Hwan Jung, Young-In Yoon, Gi-Won Song, Gil-Chun Park, Tae Won Kim, Jung-Man Namgoon, Shin Hwang, Eunyoung Tak, Sung-Gyu Lee
Cancers.2026; 18(6): 1038. CrossRef
Phytoconstituents and Molecular Docking of Ethanol Extract of Sargassum aquifolium J. Agardh with Different Apoptosis Proteins Involved in Hepatocellular Carcinoma
Anak Agung Ayu Putri Permatasari, Putu Angga Wiradana, I Gede Widhiantara, Ni Kadek Yunita Sari, I Made Gde Sudyadnyana Sandhika, Mochammad Aqilah Herdiansyah, Win Darmanto, Novaria Sari Dewi Panjaitan
Biomedical & Pharmacology Journal.2026; 1(19): 398. CrossRef
Nuclear prostaglandin E synthase 3 promotes hepatocellular carcinoma growth with immunosuppressive macrophage polarization via the SP1/TGF-β axis
Nianfei Wang, Wei Chen, Shumin Shen, Jian Qi, Shanghu Wang, Rong Wang, Ming Li, Zixiang Chen, Jiangming Chen, Bo Hong, Hongzhi Wang
Molecular Biomedicine.2026;[Epub] CrossRef
Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world study
Huifang Kong, Yan Chen, Hong Li, Di Wang, Xiujuan Chang, Zhen Zeng, Wei Zhang
The Oncologist.2026;[Epub] CrossRef
CXCR4-Targeted Nanotherapeutics: A Promising Approach for Liver Fibrosis and Hepatocellular Carcinoma Management
Aftab Ullah, Marina Khan, Yibang Zhang, Muhammad Shafiq, Mohsan Ullah, Azar Abbas, Kifayat Ullah, Xu Xiangxiang, Gang Chen, Yong Diao
International Journal of Nanomedicine.2026; Volume 21: 1. CrossRef
An automated and portable magnetically-controlled microfluidic chip platform with dual detection modes for sensitive AFP quantification
Peng Zhang, Chenqi Zhang, Min Jia, Yongdong Pan, Shuo Wu, Jianxin Cheng, Lujie Song, Zizhen Ming
Analytica Chimica Acta.2026; 1408: 345570. CrossRef
Hepatocellular carcinoma risk, net survival and relative survival ratio in a high-income country of the Eastern Mediterranean Region: 2008–2020
Saeed Akhtar, Shaimaa Almohaid
BMC Gastroenterology.2026;[Epub] CrossRef
Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort
Nicole Shu Ying Tang, Ethan Kai Jun Tham, Nicholas Syn, Ken Liu, Gang Chen, Beom Kyung Kim, Mark Muthiah, Takumi Kawaguchi, Asahiro Morishita, Sung Won Lee, Karn Wijarnpreecha, Hirokazu Takahashi, Daniel Q. Huang
Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Targeting the AMPK/ACC pathway with luteolin suppresses de novo lipogenesis and limits tumor burden in a MASH-HCC mouse model
Gaoxuan Shao, Chenceng Sun, Chenhao Ye, Ying Liu, Jiashu Pan, Yujing Liu, Lu Lu, Lei Wang, Zemin Lin, Fan Yang, Guang Ji, Hanchen Xu
Life Sciences.2026; 397: 124440. CrossRef
Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab
Shuyue Xiao, Xiaohui Huang, Shuer Liu, Di Jin, Zheng Liu
Nutrition and Cancer.2025; 77(2): 244. CrossRef
Structure–activity relationship studies of Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine derivatives to develop selective FGFR inhibitors as anticancer agents for FGF19-overexpressed hepatocellular carcinoma
Jisook Kim, Seung Hyun Jung, Joo Chan Lee, Won Jeoung Kim, Jooyun Byun, Young Gil Ahn, Hyun-Ju Park
European Journal of Medicinal Chemistry.2025; 282: 117047. CrossRef
Liver cancer in Saudi Arabia: A registry-based nationwide descriptive epidemiological and survival analysis
Nawal H. Almohammadi
Cancer Epidemiology.2025; 94: 102731. CrossRef
Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression
Steffen Markus Heckl, Carolin Schneider, Lukas Kercher, Hans-Michael Behrens, Jan-Paul Gundlach, Alexander Bernsmeier, Stephan Schmidt, Sandra Krüger, Felix Braun, Rainer Günther, Thomas Becker, Stefan Schreiber, Christoph Röcken
Scientific Reports.2025;[Epub] CrossRef
Therapeutic Effects of Crocin Nanoparticles Alone or in Combination with Doxorubicin against Hepatocellular Carcinoma In vitro
Noha S. Basuony, Tarek M. Mohamed, Doha M. Beltagy, Ahmed A. Massoud, Mona M. Elwan
Anti-Cancer Agents in Medicinal Chemistry.2025; 25(3): 194. CrossRef
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Masaud Shah, Muhammad Hussain, Hyun Goo Woo
Genomics & Informatics.2025;[Epub] CrossRef
Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
Clinical and Molecular Hepatology.2025; 31(1): 166. CrossRef
Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B
Log Young Kim, Jae Young Kim, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
Journal of Medical Virology.2025;[Epub] CrossRef
Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma
Dong Hyun Kim, Eun Min Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Gi Hong Choi, Sang Hoon Ahn, Hye Won Lee, Do Young Kim
Cancers.2025; 17(4): 566. CrossRef
Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
Hyuk Kim, Jae-Young Kim, Yoon E. Shin, Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Scientific Reports.2025;[Epub] CrossRef
Targeting metabolic diseases with celastrol: A comprehensive review of anti-inflammatory mechanisms and therapeutic potential
Xiaojuan Wang, Mohamad Hafizi Abu Bakar, Song Liqun, Mohd Asyraf Kassim, Khairul Anuar Shariff, Thiruventhan Karunakaran
Journal of Ethnopharmacology.2025; 344: 119560. CrossRef
Advancements in autoimmune hepatitis epidemiology, treatment and complication – a 15-year retrospective study
Mifleh Tatour, Fadi Abu Baker, Tarek Saadi, Ahmad Yahia, Rawi Hazzan
Clinics and Research in Hepatology and Gastroenterology.2025; 49(4): 102570. CrossRef
Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia‐Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021
Suprabhat Giri, Sushrut Ingawale, Gaurav Khatana, Prasanna Gore, Dibya Lochan Praharaj, Vincent Wai‐Sun Wong, Daniel Q. Huang, Amit Singhal, Ashok Choudhury
Journal of Gastroenterology and Hepatology.2025; 40(5): 1188. CrossRef
Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
Piotr Starnawski, Klaudia Nowak, Zuzanna Augustyn, Dominik Malicki, Aleksandra Piąta, Dominika Lorek, Jakub Janczura
Medical Oncology.2025;[Epub] CrossRef
Investigating the functional role of BUB1B in aflatoxin B1-associated hepatocarcinogenesis
Hayam Hamdy, Wafaa A. Aly, Eyad Elkord
Toxicology.2025; 514: 154127. CrossRef
Synergistic effects of L-arginine and argininosuccinate synthetase 1 in inducing apoptosis in hepatocellular carcinoma
Jin Sun Kim, Won-Mook Choi, Ha-Il Kim, Sung Won Chung, Jonggi Choi, Danbi Lee, Kang Mo Kim
Journal of Liver Cancer.2025; 25(1): 79. CrossRef
Association between allopurinol and hepatocellular carcinoma: analysis of genetic risk and patient survival
Yu-fu Li, Hui-wei Wang, Huan-yan Peng, Zhen-ying Zhang, Zhi-jia Yao, Yuan Meng, Dong-ye Yang
Discover Oncology.2025;[Epub] CrossRef
A Comparative Analysis of the Roles of von Willebrand Factor and ADAMTS13 in Hepatocellular Carcinoma: A Bioinformatics and Microarray-Based Study
Durmuş Ayan, Şerife Buket Bozkurt Polat, Ergül Bayram, Esma Özmen, Fatma Esin Aydın, Serpil Ersan
Current Issues in Molecular Biology.2025; 47(4): 270. CrossRef
Hepatitis B virus genotype distribution and mutation patterns: Insights and clinical implications for hepatitis B virus positive patients
Manisha M Ratnaparkhi, Chanda R Vyawahare, Nageswari R Gandham
World Journal of Experimental Medicine.2025;[Epub] CrossRef
Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
Hyuk Soo Eun
Clinical and Molecular Hepatology.2025; 31(2): e215. CrossRef
Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma
Xinyi Li, Zifan Qin, Haozhi Chen, Daichuan Chen, Nafisa Alimu, Duoduo Li, Xiyu Cheng, Qiong Yan, Lishu Zhang, Xingwei Liu, Zitong Zhou, Jiayi Zhu, Hangqi Ma, Xinyue Pei, Hanli Xu, Jiaqiang Huang
International Journal of Immunopathology and Pharmacology.2025;[Epub] CrossRef
Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
Liver International.2025;[Epub] CrossRef
Bioinformatics-driven identification of key non-invasive prognostic biomarkers in hepatocellular carcinoma
Muhammad-Redha Abdullah-Zawawi, Muhammad Irfan Abdul Jalal, Shing Cheng Tan, Loscheni Varma, Nur Alyaa Afifah Md Shahri, Mira Farzana Mohamad Mokhtar, Ryia Illani Mohd Yunos, Nurul Syakima Ab Mutalib, Rahman Jamal
Egyptian Journal of Medical Human Genetics.2025;[Epub] CrossRef
Marine L-arginase encapsulated in poly (lactic-co-glycolic acid) nanoparticles: A novel anti-cancer strategy for effective hepatocellular carcinoma treatment in vitro and in vivo
Amria M. Mousa, Mohamed Abdelraof, Amany A. Hassabo, Doaa A. Darwish, Mona M.A. Abdel-Mottaleb, Rasha M. Allam
Journal of Drug Delivery Science and Technology.2025; 109: 106980. CrossRef
Redefining precision medicine in hepatocellular carcinoma through omics, translational, and AI-based innovations
Rashi Jain, Sathish Kumar Mungamuri, Prabha Garg
The Journal of Precision Medicine: Health and Disease.2025; 1: 100003. CrossRef
Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis
Yongjuan Wu, Guangyuan Cheng, Jun Han, Qingsong Yang
Clinical and Experimental Medicine.2025;[Epub] CrossRef
Exploring the antitumor potential of cucurbitacin B in hepatocellular carcinoma through network pharmacology, molecular docking, and molecular dynamics simulations
Hongyu Zhang, Baixiu Wu, Liuhua Ke, Xiaoyuan Fan, Liji Huang, Zheng Peng
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(11): 14751. CrossRef
Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD/DEN/TAA in a rat model: regulation of AMPK/HIF-1α/YAP-1/TAZ signaling pathways
Hany M. Fayed, Gihan F. Asaad, Marawan A. Elbaset, Ola A. Sharaf, Sawsan S. Mahmoud, Mohamed M. Amin, Zeinab A. El-Gendy, Fatma A. Ibrahim, Sherein S. Abdelgayed, Rehab F. Abdel-Rahman
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(11): 16131. CrossRef
The use of artificial intelligence in stereotactic ablative body radiotherapy for hepatocellular carcinoma
Atsuto Katano
Frontiers in Medicine.2025;[Epub] CrossRef
Extracellular vesicles as a promising platform of precision medicine in liver cancer
Keyang Xu, Qibiao Wu, Zhao Lingyun, Romario Nguyen, Fatema Safri, William Yang, Yikun Xu, Yun Ye, Hiu Yee Kwan, Qiang Wang, Xiuming Liang, Muhammad J.A. Shiddiky, Majid E. Warkiani, Jacob George, Liang Qiao, Jianfeng Bao
Pharmacological Research.2025; 217: 107800. CrossRef
Spinal Cord Infarction After Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report
Tho Tran Dinh, Sy Than Van, Vinh Chu Van, Phuc Chu Minh
Cureus.2025;[Epub] CrossRef
Association between early job loss and prognosis among hepatocellular carcinoma survivors
B Yun, J Oh, S H Ahn, B K Kim, J-H Yoon
Occupational Medicine.2025; 75(2): 113. CrossRef
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study
Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho
JHEP Reports.2025; 7(9): 101477. CrossRef
Low-Abundance Serum Protein Biomarker Candidates for HCC in Patients with Liver Cirrhosis
Muhammad Salman Sajid, Rency S. Varghese, Alexander Kroemer, Habtom W. Ressom
Journal of Proteome Research.2025; 24(7): 3656. CrossRef
Roadmap for HCC Surveillance and Management in the Asia Pacific
Masatoshi Kudo, Bui Thi Oanh, Chien-Jen Chen, Do Thi Ngat, Jacob George, Do Young Kim, Luckxawan Pimsawadi, Pisit Tangkijvanich, Raoh-Fang Pwu, Rosmawati Mohamed, Sakarn Bunnag, Sheng-Nan Lu, Sirintip Kudtiyakarn, Tatsuya Kanto, Teerha Piratvisuth, Chao-C
Cancers.2025; 17(12): 1928. CrossRef
Computational Repurposing of Approved Drugs: Exploring New Therapeutic Avenues for Liver Disorders
Pranali Jadhav, Asha Thomas, Somdatta Chaudhari, Sohan Chitlange
Journal of Pharmaceutical Innovation.2025;[Epub] CrossRef
Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches
Sherif A. El-Kafrawy, Mostafa S. Elkafrawy, Esam I. Azhar, Anwaar Saeed, Ashraf A. Tabll
Frontiers in Immunology.2025;[Epub] CrossRef
Pathogenic effects of telomerase reverse transcriptase (TERT) promoter mutations in nonalcoholic steatohepatitis (NASH) related hepatocellular carcinoma (HCC) and its potentials as a diagnostic biomarker
Usman Umar Liman, Asanka Sudeshini Hawage, Sumadee De Silva, Saumya Madushani Samarasinghe, Kamani Hemamala Tennekoon, Rohan Chaminda Siriwardana, Madunil Anuk Niriella
Egyptian Journal of Medical Human Genetics.2025;[Epub] CrossRef
Perspectives on NcRNAs in HBV/cccDNA-driven HCC progression
Yang-Hsiang Lin, Ming-Wei Lai, Chau-Ting Yeh, Wey-Ran Lin
Cancer Cell International.2025;[Epub] CrossRef
Burden of liver cancer in the European region from 1990 to 2021: a sub-analysis of the global burden of disease study
Onika Kazi, Shokoufeh Hamidzadeh, Babak Ehsani Zunuz, Abdolsabour Khordoo, Seyede Saba Mazloomi, Hossein Khademsedaghat, Mohammad Amin Khadembashiri
Annals of Medicine & Surgery.2025; 87(7): 4053. CrossRef
Systemic treatment of liver cancer: Current status and future perspectives
Chun-Bo Li, Yu-Ting Ning, Nai-Ying Shen, Ben Wang, Han Xiao, Gang Luo
World Journal of Hepatology.2025;[Epub] CrossRef
Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review
Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Claudio Basile, Carlo Palma, Paolo Vaia, Marcello Dallio, Alessandro Federico
Diabetology.2025; 6(8): 79. CrossRef
Rapid Bone Metastasis in Hepatocellular Carcinoma: A Case Report
Laraib ., Uzma Khalid, Ayesha Khalid
Cureus.2025;[Epub] CrossRef
Multi-Omics Feature Selection to Identify Biomarkers for Hepatocellular Carcinoma
Rency S. Varghese, Xinran Zhang, Sarada Giridharan, Muhammad Salman Sajid, Md Mamunur Rashid, Alexander Kroemer, Habtom W. Ressom
Metabolites.2025; 15(9): 575. CrossRef
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study
Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae
Journal of Gastroenterology.2025; 60(10): 1284. CrossRef
Emodin promotes GSK-3β-mediated PD-L1 proteasomal degradation and enhances anti-tumor immunity in hepatocellular carcinoma
Xuemei Yang, Weiguang Chen, Haitao Sun, Weicong Chen, Wei Xu, Chunyu He, Yang Liu, Ying Kuang, Yanhao Ma, Binglian Zhong, Chaojie Li, Guohuan Li, Qingfeng Du, Songqi He
Chinese Medicine.2025;[Epub] CrossRef
Direct-acting Antivirals Therapy for Hepatocellular Carcinoma in Hepatitis C Patients
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Journal of Digestive Cancer Research.2025; 13(2): 150. CrossRef
Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma
Ahmed I. Foudah, Mohammed H. Alqarni, Tariq M. Aljarba, Talha Jawaid, Osama A. Alkhamees, Saud M. Alsanad, Khalid I. AlHussaini, Aftab Alam
Molecular Diversity.2025;[Epub] CrossRef
Association between metabolites and hepatocellular carcinoma: findings from a two-sample Mendelian randomization study
Tung Hoang, Van Mai Truong, Tho Thi Anh Tran, Bao Le Thai Tran, Ngoc Hong Cao
Journal of Liver Cancer.2025; 25(2): 251. CrossRef
Fig Seed Oil Induces Mitochondrial-Mediated Apoptosis in HepG2 Cells
Adem Yavaş
SDÜ Tıp Fakültesi Dergisi.2025; 32(3): 230. CrossRef
Heme Oxygenase-1 Expression as a Prognostic Marker in Early-Stage HCC Undergoing Resection or Liver Transplantation
Ramona Cadar, Alin Mihai Vasilescu, Ana Maria Trofin, Alexandru Grigorie Nastase, Mihai Zabara, Cristina Muzica, Corina Lupascu Ursulescu, Mihai Danciu, Andrei Pascu, Iulian Buzincu, Delia Ciobanu, Ianole Victor, Cristian Dumitru Lupascu
Life.2025; 15(10): 1589. CrossRef
Quantification, antioxidant, in-silico molecular docking and anti-hepatocellular carcinoma activity of Sepia ink polysaccharides prepared from Sepia pharaonis
Sandhanam Kuppusamy, Bedanta Bhattacharjee, Abarnadevika Alagiri, Sumithra Mohan, Ram Kumar Sahu, Abhishek Bhattacharjee, Chitra Vellapandian
Future Journal of Pharmaceutical Sciences.2025;[Epub] CrossRef
MicroRNA Landscape in Hepatocellular Carcinoma: Metabolic Re-Wiring, Predictive and Diagnostic Biomarkers, and Emerging Therapeutic Targets
Dimitris Liapopoulos, Panagiotis Sarantis, Theodora Biniari, Thaleia-Eleftheria Bousou, Eleni-Myrto Trifylli, Ioanna A. Anastasiou, Stefania Kokkali, Dimitra Korakaki, Spyridon Pantzios, Evangelos Koustas, Ioannis Elefsiniotis, Michalis V. Karamouzis
Biomedicines.2025; 13(9): 2243. CrossRef
Current status and future perspectives of minimally invasive liver surgery for hepatocellular carcinoma
Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, Hyelim Joo, Seung Yeon Lim
Journal of Liver Cancer.2025; 25(2): 233. CrossRef
Navigating liver cancer with mouse models: a comprehensive overview of HCC experimental systems
Ga-Young Kim, Dokyung Kim, Jaehyun Jeon, Wonhyo Seo, Seol Hee Park
Journal of Liver Cancer.2025; 25(2): 239. CrossRef
Effects of the Polar Fraction of Lophocereus schottii on Gene Expression and Hepatocyte Proliferation in a Wistar Rat Model of Hepatocellular Carcinoma
Marina Campos-Valdez, Jaime Sánchez-Meza, Arturo Orozco-Barocio, José A. Domínguez-Rosales, Juliana Marisol Godínez-Rubí, Sarai C. Rodríguez-Reyes, Erika Martínez-López, Miriam R. Bueno-Topete, Manuel A. Castro-García, Guillermo M. Zúñiga-González, Daniel
International Journal of Molecular Sciences.2025; 26(19): 9788. CrossRef
Radiomic Analysis in Hepatocellular Carcinoma: Prospects and Clinical Benefits (Review)
E. B. Kodzoeva, K. A. Romanova, B. M. Medvedeva, N. Ts. Drobot
Journal of oncology: diagnostic radiology and radiotherapy.2025; 8(3): 78. CrossRef
Biodistribution and Radiation Dosimetry of [68Ga]Ga-RAYZ-8009, a Glypican 3–Targeting Compound for Imaging of Hepatocellular Carcinoma
Oliver Viering, Julia Brosch-Lenz, Ralph A. Bundschuh, Helen Scholtissek, Johanna S. Enke, Adriana Amerein, Georgine Wienand, Alexander Dierks, Malte Kircher, Marianne Patt, Christian H. Pfob, Constantin Lapa
Journal of Nuclear Medicine.2025; 66(11): 1737. CrossRef
Evaluating the Antitumor Effect of Root Extract of Salvadora persica in Hepatocarcinoma Through the Induction of Apoptosis via an Intrinsic Pathway: An In Vitro Study
Fouzia Latif, Kong Qun, Mingjing Lu
Cureus.2025;[Epub] CrossRef
Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir
Hyuk Kim, Jae Young Kim, Hye-Jin Yoo, Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Scientific Reports.2025;[Epub] CrossRef
Arachidonic acid induces ferroptosis in hepatocellular carcinoma via the SIRT5-ACSL4/LPCAT3/ALOX15 axis, leading to lipid peroxidation and mitochondrial dysfunction
Peisen Xue, Jingting Zhang, Zhibing Wang, Ling Wu, Jincheng Tang, Renyi Yang, Wenhui Gao, Puhua Zeng
Phytomedicine.2025; 148: 157450. CrossRef
Quantitative Ultrasound Assessment of Liver Fat Using Deep Learning and Clinical Data Integration
Jirakorn Jamrasnarodom, Terapap Apiparakoon, Sanparith Marukatat, Oracha Chaichuen, Sasima Sukchareon, Roongruedee Chaiteerakij
Journal of Medical and Biological Engineering.2025; 45(6): 817. CrossRef
Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations
Muhammad Rezki Rasyak, Sri Jayanti, Cyrollah Disoma, Bens Pardamean, Caecilia Sukowati
Exploration of Targeted Anti-tumor Therapy.2025;[Epub] CrossRef
Circulating miRNAs combined with AFP improve diagnostic accuracy for HBV-associated hepatocellular carcinoma
Ngo Dieu Hoa, Dao Phuong Giang, Nguyen Thi Thu Hien, Dang Thi Ngoc Dung, Mai Thanh Binh, Ngo Tat Trung, Tran Thi Thanh Huyen, Hoang Van Tong, Thirumalaisamy P. Velavan, Le Huu Song, Nghiem Xuan Hoan
Biochemistry and Biophysics Reports.2025; 44: 102343. CrossRef
A contrast‑enhanced CT histogram‑driven nomogram for predicting post‑radiotherapy liver regeneration in hepatocellular carcinoma
Bo Liu, Yuan Xu, Xijie Zhang, Wei Qi, Bo Ren, Wenjia Kong, Wence Zhou
Radiation Oncology.2025;[Epub] CrossRef
–A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative
Yan An, Xiangyang Shi, Wentao Huang, Mingyi Shang, Guang-Zhi Jin
Journal of Translational Medicine.2025;[Epub] CrossRef
Advanced Hepatocellular Carcinoma Missed on Ultrasonography: A Case Report
Tom Ryu, Jae Young Jang, Yon Hee Kim, Young Chang, Soung Won Jeong
Clinical Ultrasound.2025; 10(2): 114. CrossRef
Personalized Mortality Risk Stratification in ALD- and MASLD-Related Hepatocellular Carcinoma Using a Machine Learning Approach
Miguel Suárez, Sergio Gil-Rojas, Pablo Martínez-Blanco, Ana M. Torres, Natalia Martínez-García, Miguel Torralba, Jorge Mateo
Metabolites.2025; 16(1): 8. CrossRef
Clinicopathological profile of gastrointestinal tract malignancies: A retrospective study.
Bhupendra Singh Chahar, Gull Mohammad Mohammad Bhat, Ram Krishna, Anushree Chaturvedi, Chander Dutti, Sourav Debnath, Naman Bansal
Asian Journal of Oncology.2025; 11: 23. CrossRef
Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma
Susan J. Kim, Kaelyn C. Cummins, Allan Tsung
Cancers.2024; 16(10): 1852. CrossRef
Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon
Linda Galasso, Lucia Cerrito, Valeria Maccauro, Fabrizio Termite, Irene Mignini, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
International Journal of Molecular Sciences.2024; 25(13): 7191. CrossRef
Impacts of smoking on alcoholic liver disease: a nationwide cohort study
Jeong-Ju Yoo, Dong Hyeon Lee, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Log Young Kim
Frontiers in Public Health.2024;[Epub] CrossRef
Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies
Fouad Jaber, George Cholankeril, Hashem B El-Serag
Journal of the Canadian Association of Gastroenterology.2024; 7(5): 331. CrossRef
Development and validation of a prognostic nomogram to predict the recurrence of AFP-negative and DCP-positive hepatocellular carcinoma after curative resection
Junnan Li, Qi Wang, Yadong Yan, Lina Sun, Gongming Zhang, Guangming Li, Ronghua Jin
Frontiers in Oncology.2024;[Epub] CrossRef
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
Baofa Yu, Wenxue Ma
Cytokine & Growth Factor Reviews.2024; 79: 29. CrossRef
Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets
Yazan Abboud, Vraj P. Shah, Michael Bebawy, Ahmed Al-Khazraji, Kaveh Hajifathalian, Paul J. Gaglio
Journal of Clinical Medicine.2024; 13(17): 5256. CrossRef
Bridging hope: Retrospective analysis of stereotactic radiotherapy in patients with hepatocellular carcinoma-A promising and cost-effective solution for low-and middle-income countries
Rakesh Kapoor, Treshita Dey, Divya Khosla, Sunil Taneja, Naveen Kalra, Rajesh Gupta
Cancer Research, Statistics, and Treatment.2024; 7(3): 326. CrossRef
Absence of Survival Impact from Hepatitis During Immunotherapy in 193 Patients with Advanced Hepatocellular Carcinoma – An Observational Study from Taiwan
Chi-Han Lin, Yung-Chia Kuo, Hsuan-Chih Kuo, Ching-Ting Wang, Shi-Ming Lin, Alan Chao-Wei Lee, Ming-Chin Yu, Wei-Chen Lee, Cherry Chiao-Erh Chen, Jason Chia-Hsun Hsieh
Journal of Hepatocellular Carcinoma.2024; Volume 11: 1875. CrossRef
A Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review
Yoon-E Shin, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Medicina.2024; 60(10): 1634. CrossRef
Management of non-alcoholic fatty liver disease-associated hepatocellular carcinoma
Peijun Xu, Maoyun Liu, Miao Liu, Ai Shen
BioScience Trends.2024; 18(5): 431. CrossRef
Gene targets with therapeutic potential in hepatocellular carcinoma
Syifaus Shodry, Yuliono Trika Nur Hasan, Iwal Reza Ahdi, Zulvikar Syambani Ulhaq
World Journal of Gastrointestinal Oncology.2024; 16(12): 4543. CrossRef
Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022
Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang
The Korean Journal of Internal Medicine.2024; 39(6): 931. CrossRef
Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
Han Ah Lee
The Ewha Medical Journal.2024;[Epub] CrossRef
Lower Incidence of Hepatocellular Carcinoma with Tenofovir Alafenamide in Chronic Hepatitis B: Evidence from a Large-Scale Cohort
Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Hye Won Lee, Sang Gyune Kim, Young Seok Kim
JHEP Reports.2024; : 101268. CrossRef
Microwave ablation versus single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: A randomized control trial
Katsutoshi Sugimoto, Kento Imajo, Hidekatsu Kuroda, Go Murohisa, Kazue Shiozawa, Kentaro Sakamaki, Takuya Wada, Hirohito Takeuchi, Kei Endo, Tamami Abe, Takashi Matsui, Takahiro Murakami, Masato Yoneda, Atsushi Nakajima, Shigehiro Kokubu, Takao Itoi
JHEP Reports.2024; : 101269. CrossRef
The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
Wonju Chung, Haeryoung Kim
The Ewha Medical Journal.2024;[Epub] CrossRef
Enhancing global hepatocellular carcinoma management: Bridging Eastern and Western perspectives on dexamethasone and N-acetylcysteine before transarterial chemoembolization
Thang Viet Luong, Nam Van Duc Nguyen, Linh Duy Le, Hieu Nguyen Hoang Minh, Hai Nguyen Ngoc Dang
World Journal of Gastroenterology.2024; 30(47): 4983. CrossRef
Predicting Microvascular Invasion in Liver Transplant Recipients for Hepatocellular Carcinoma
Usman I Aujla, Imran Ali Syed, Kashif Rafi, Ammara Naveed, Ahmad K Malik, Muhammad Yasir Khan, Ihsan Ul Haq, Sohail Rashid, Osama T Butt, Faisal Dar
Cureus.2024;[Epub] CrossRef
The Influence of Sex and Age on Survival in Patients with Hepatocellular Carcinoma
Iuliana Pompilia Radu, Bernhard Scheiner, Jonas Schropp, Maria Gabriela Delgado, Birgit Schwacha-Eipper, Chaonan Jin, Jean-Francois Dufour, Matthias Pinter
Cancers.2024; 16(23): 4023. CrossRef
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro
Viruses.2024; 16(12): 1899. CrossRef
Statin use and liver-related prognosis among patients with MASLD
Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
JHEP Reports.2024; : 101313. CrossRef
Long-term results of surgical treatment of hepatocellular cancer in Russian real practice
V. V. Petkau, R. I. Rasulov, A. A. Muratov, G. V. Nurbekyan, I. B. Uvarov, A. A. Kirshin, R. V. Orlova, N. V. Popova, M. S. Dinikin, R. Yu. Khlobystin, A. V. Sultanbaev, K. V. Menshikov, O. G. Orlov
Meditsinskiy sovet = Medical Council.2024; (21): 114. CrossRef
Overall Survival and the Impact of Albumin-bilirubin Grade in Patients with Advanced Hepatocellular Carcinoma: Data from a Tertiary Care Hospital in a Lower-middle-income Country
Mohammad SS Naviwala, Waqas A Khan, Adeeba Zaki, Mahnoor Tariq, Faiza Ahmed, Warda Saleem, Munira Moosajee, Yasmin A Rashid
Euroasian journal of hepato-gastroenterology.2024; 14(2): 251. CrossRef
The roles and mechanisms of miRNA in HBV-HCC carcinogenesis: Why no therapeutic agents after 30 years?
KURT SARTORIUS, BENN SARTORIUS, CHERIE WINKLER, ANIL CHUTURGOON, ANNA KRAMVIS, PING AN, WEIGANG ZHANG, YUNJIE LU
BIOCELL.2024; 48(11): 1543. CrossRef

Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Darine Daher, Karim Seif El Dahan, Amit G. Singal; J Liver Cancer. 2023;23(1):127-142. Published online February 9, 2023; DOI: https://doi.org/10.17998/jlc.2022.12.30

28,503 Views
444 Downloads
36 Citations

Abstract PDF

Non-alcoholic fatty liver disease (NAFLD), one of the most common causes of liver disease, is an increasingly common cause of hepatocellular carcinoma (HCC). Several demographic, clinical, and genetic factors contribute to HCC risk in NAFLD patients, which may inform risk stratification scores. Proven efficacious approaches to primary prevention approach in patients with non-viral liver disease remain an area of need. Semi-annual surveillance is associated with improved early tumor detection and reduced HCC-related mortality; however, patients with NAFLD have several challenges to effective surveillance, including under-recognition of at-risk patients, low surveillance utilization in clinical practice, and lower sensitivity of current tools for early-stage HCC detection. Treatment decisions are best made in a multidisciplinary fashion and are informed by several factors including tumor burden, liver dysfunction, performance status, and patient preferences. Although patients with NAFLD often have larger tumor burden and increased comorbidities compared to counterparts, they can achieve similar post-treatment survival with careful patient selection. Therefore, surgical therapies continue to provide a curative treatment option for patients diagnosed at an early stage. Although there has been debate about the efficacy of immune checkpoint inhibitors in patients with NAFLD, current data are insufficient to change treatment selection based on liver disease etiology.

Citations

Citations to this article as recorded by

Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH
Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang, Jiao Xiao, Xiongjin Tan, Xun Chen, Peili Wu, Yukun Li
npj Digital Medicine.2026;[Epub] CrossRef
Comparison of transient elastography and shear wave elastography as a routine diagnostic method for assessing liver fibrosis in Indian participants with liver steatosis
Mukulesh Gupta, Dinesh Kumar, K. P. Chandra, Anuj Maheshwari
International Journal of Diabetes in Developing Countries.2026;[Epub] CrossRef
Direct Viral Mechanisms Underlying the Onset of HBV-Related Hepatocellular Carcinoma and Implications for Therapeutic Strategies
Simone La Frazia, Alessia Magnapera, Lorenzo Piermatteo, Stefano D’Anna, Leonardo Duca, Valentina Svicher, Romina Salpini
Viruses.2026; 18(2): 185. CrossRef
Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses
Fausto Petrelli, Silvia Colombo, Lorenzo Dottorini, Mara Ghilardi, Annamaria De Giorgi, Gianluca Tomasello, Giulio Carcano, Michele Ghidini
Critical Reviews in Oncology/Hematology.2026; 221: 105248. CrossRef
Hepatocellular Carcinoma Over Three Decades: from Screening Evolution to Integrated Therapeutic Strategies
Ke Huang, Myoung Ok Kim
Journal of Cancer Prevention.2026; 31(2): 54. CrossRef
The multifaceted anticancer potential of luteolin: involvement of NF-κB, AMPK/mTOR, PI3K/Akt, MAPK, and Wnt/β-catenin pathways
Deepika Singh, Gaurav Shukla
Inflammopharmacology.2025; 33(2): 505. CrossRef
Coenzyme Q and Selenium Co-Supplementation Alleviate Methionine Choline-Deficient Diet-Induced Metabolic Dysfunction-Associated Steatohepatitis in Mice
Hyewon Choi, Jiwon Choi, Yula Go, Jayong Chung
Nutrients.2025; 17(2): 229. CrossRef
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis
Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Hepatology International.2025; 19(4): 959. CrossRef
MASLD or MAFLD: fatty liver by any name will pose the same challenge
Anil Chandra Anand, Dibyalochan Praharaj
Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Glycoproteomics of Gastrointestinal Cancers and Its Use in Clinical Diagnostics
Tomas Bertok, Andrea Pinkeova, Lenka Lorencova, Anna Datkova, Michal Hires, Eduard Jane, Jan Tkac
Journal of Proteome Research.2025; 24(6): 2584. CrossRef
Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease
Tom Ryu, Beom Sun Chung, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang
Phytomedicine.2025; 143: 156889. CrossRef
Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
Dong Wook Kim, Minkook Son, Hye Jung Lee, Chi Hyeon Choi, Yeo Wool Kang, Sang Yi Moon, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek, Won Suk An
Hepatology Research.2025; 55(9): 1239. CrossRef
Navigating the weight: The impact of obesity on gastrointestinal cancer surgery and strategies for improved outcomes
Gerardo Sarno, Claudia Reytor-González, Evelyn Frias-Toral, Martín Campuzano-Donoso, Christos S. Katsanos, Daniel Simancas-Racines
Seminars in Cancer Biology.2025; 114: 138. CrossRef
Clinical risk factors for hepatocellular carcinoma in Southeast Louisiana: a matched case–control study
Gabrielle V. Gonzalez, Denise M. Danos, Tekeda F. Ferguson, George Therapondos, Mei-Chin Hsieh, Claudia Leonardi
Cancer Causes & Control.2025; 36(11): 1399. CrossRef
Proteoform Patterns in Hepatocellular Carcinoma Tissues: Aspects of Oncomarkers
Elena Zorina, Natalia Ronzhina, Olga Legina, Nikolai Klopov, Victor Zgoda, Stanislav Naryzhny
Proteomes.2025; 13(3): 27. CrossRef
Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050
Jianing Shi, Xuan Wu, Jiali Yu, Qingli Zhou
Frontiers in Nutrition.2025;[Epub] CrossRef
The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health
A. O. Bueverov, N. I. Tapilskaya
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2025; 35(3): 104. CrossRef
15-Year Trends in Hepatocellular Carcinoma: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry
Songgyung Kim, Jina Park, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Ki-Hun Kim, Jonggi Choi
Gut and Liver.2025; 19(5): 746. CrossRef
Extracellular vesicles in metabolic dysfunction-associated steatotic liver disease: From intercellular signaling to clinical translation
Bootsakorn Boonkaew, Denita Charoenthanakitkul, Nuchanart Suntornnont, Chaiyaboot Ariyachet, Pisit Tangkijvanich
World Journal of Hepatology.2025;[Epub] CrossRef
Reduced risk of hepatocellular carcinoma in the use of fibrate as an add-on to statin: A retrospective population-based cohort study
Won Sohn, Sangmo Hong, Kyungdo Han, Cheol-Young Park
European Journal of Cancer.2025; 231: 116094. CrossRef
Overnutrition and Lipotoxicity: Impaired Efferocytosis and Chronic Inflammation as Precursors to Multifaceted Disease Pathogenesis
Vivek Mann, Alamelu Sundaresan, Shishir Shishodia
Biology.2024; 13(4): 241. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
Liver Cancer.2024; 13(5): 561. CrossRef
Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis
Young-Gi Song, Kyeong-Min Yeom, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo
Liver Cancer.2024; : 1. CrossRef
Emerging role of exosomal microRNA in liver cancer in the era of precision medicine; potential and challenges
Tarek El Hayek, Osama Abdulwahab Alnaser-Almusa, Sulaiman Mamoun Alsalameh, Maya Taofik Alhalabi, Ahmad Nedal Sabbah, Eman Abdullah Alshehri, Tanveer Ahmad Mir, Naresh Kumar Mani, Khaled Al-Kattan, Raja Chinnappan, Ahmed Yaqinuddin
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
Trends in alcohol use and alcoholic liver disease in South Korea: a nationwide cohort study
Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang
BMC Public Health.2024;[Epub] CrossRef
Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
Centura R. Anbarasu, Sophia Williams-Perez, Ernest R. Camp, Derek J. Erstad
Cancers.2024; 16(16): 2773. CrossRef
NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors
Nutan Sharma, Lakhwinder Singh, Aditya Sharma, Ajay Kumar, Dinesh Mahajan
Pharmacological Research.2024; 208: 107375. CrossRef
Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva
Noah J. Daniels, Courtney E. Hershberger, Matthew Kerosky, Chase J. Wehrle, Roma Raj, Nihal Aykun, Daniela S. Allende, Federico N. Aucejo, Daniel M. Rotroff
International Journal of Molecular Sciences.2024; 25(18): 10144. CrossRef
The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
Wonju Chung, Haeryoung Kim
The Ewha Medical Journal.2024;[Epub] CrossRef
Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022
Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang
The Korean Journal of Internal Medicine.2024; 39(6): 931. CrossRef
Ruptured hepatocellular carcinoma developed in a normal liver in a young patient with a body mass index of 33 kg/m2
Naoki Kirihata, Yoshiko Nakano, Koki Moriyoshi, Shin'ichi Miyamoto
BMJ Case Reports.2024; 17(12): e262841. CrossRef
Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease
Jeong-Ju Yoo, Man Young Park, Eun Ju Cho, Su Jong Yu, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon
Journal of Clinical Medicine.2023; 12(9): 3336. CrossRef
Reply: Validation of MELD 3.0 scoring system in East Asian patients with cirrhosis awaiting liver transplantation
Jeong-Ju Yoo, Sang Gyune Kim
Liver Transplantation.2023; 29(11): E38. CrossRef
Unraveling the Janus-Faced Role of Autophagy in Hepatocellular Carcinoma: Implications for Therapeutic Interventions
Thi Ha Nguyen, Tuan Minh Nguyen, Dinh Thi Minh Ngoc, Taesik You, Mi Kyung Park, Chang Hoon Lee
International Journal of Molecular Sciences.2023; 24(22): 16255. CrossRef
Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
Ji Kim, Hee-Chul Nam, Chang-Wook Kim, Hee Cho, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Hyun Yang, Si Bae, Suho Kim, Jung Oh, Ho Chun, Chang Jeon, Jaegyoon Ahn, Pil Sung
Cancers.2023; 15(17): 4233. CrossRef
A nationwide study on the current treatment status and natural prognosis of hepatocellular carcinoma in elderly
Jeong-Ju Yoo, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park
Scientific Reports.2023;[Epub] CrossRef

Case Report

A Case of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Seok, Jun , Suk, Ki Tae , Kim, Dong Joon; J Liver Cancer. 2018;18(1):51-54. Published online March 31, 2018; DOI: https://doi.org/10.17998/jlc.18.1.51

2,936 Views
49 Downloads

Abstract PDF: Non-alcoholic fatty liver disease (NAFLD) has been one of the causes of cryptogenic hepatocellular carcinoma (HCC). NAFLD-associated HCC (NAFLD-HCC) have clinical features such as high body mass index, deranged lipid profiles, or diabetes mellitus. We experienced a 72-year–old woman with NAFLD associated HCC which was recurred after surgical resection.

Review Articles

Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Hyunwoo Oh, Dea Won Jun; J Liver Cancer. 2017;17(2):117-125. Published online September 30, 2017; DOI: https://doi.org/10.17998/jlc.17.2.117

4,534 Views
125 Downloads

Abstract PDF: Hepatocellular carcinoma (HCC) is one of the most common life-threatening cancers worldwide. Recently, many patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have progressed to HCC even in the absence of cirrhosis. As the morbidity of metabolic syndrome increases, the proportion of HCC associated with NAFLD is expected to increase gradually. A new mechanism for the development of HCC in NAFLD has been identified; Diabetes mellitus, insulin resistance, obesity, lipotoxicity, gut dysbiosis are risk factors. Inflammatory cytokines such as adipokines, leptin, tumor necrosis factor-α, interlukin-8, nuclear factor-κB constitute dysplasia-carcinoma sequence. At the time of diagnosis, NAFLD/ NASH related HCC tend to progress to larger and in advanced tumor-node-metastasis stages compared to viral hepatitis related HCC. But there are no guidelines for early detection of NAFLD-related HCC. So, it is essential to study the screening program for the early detection of NAFLD-related HCC and precise methods for NAFLD.

Obesity and Hepatocellular Carcinoma: Won Sohn; J Liver Cancer. 2016;16(2):86-91. Published online September 30, 2016; DOI: https://doi.org/10.17998/jlc.16.2.86

1,988 Views
29 Downloads

Abstract PDF: Obesity is closely associated with hepatocellular carcinoma (HCC) as well as other malignancies. Obesity is an important risk factor for cancer development and overall mortality in HCC. Molecular mechanisms of hepatocarcinogenesis in obesity are adipose tissue remodeling, dysregulation of adipokines, increased reactive oxygen species, insulin resistance or hyperinsulinemia, alteration of gut microbiota, and dysregulation of microRNA. Obesity is the most common cause of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). NAFLD or NASH leads to HCC as well as liver cirrhosis. Hepatitis C virus regulates lipid homeostasis in liver. Obesity and its’ related factors (metabolic syndrome and diabetes mellitus) are significantly related to the risk of HCC development in chronic hepatitis C. However, it is not clear whether obesity is a risk factor for HCC in chronic hepatitis B. The relationship between obesity and HCC seems to be different according to etiology of background liver disease. Further studies are needed to clarify the effect of obesity on HCC in different etiologies of chronic liver disease.

Pathogenic Mechanism of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Sun Min Kim, Joo Hyun Sohn; J Liver Cancer. 2014;14(2):63-72. Published online September 30, 2014; DOI: https://doi.org/10.17998/jlc.14.2.63

1,879 Views
35 Downloads

Abstract PDF: Non-alcoholic fatty liver disease (NAFLD) is a clinicopathologic condition that shows excessive fat accumulation in hepatocytes without significant alcohol intake, other liver diseases and the history of using hepatotoxic drugs. Recently, the incidence of hepatocellular carcinoma (HCC) related to NAFLD is increasing. However, the pathogenic mechanism of HCC developed from NAFLD has not been fully known. The most important pathogenic factor which affects the development of HCC is cirrhosis itself from any causes including NAFLD. To date, it is considered that NAFLD can cause HCC through insulin resistance, oxidative stress, and inflammatory process. In NAFLD, insulin resistance and its resulting hyperinsulinemia increase insulin-like growth factor-1 (IGF-1), which leads to cell growth and inhibition of apoptosis. Furthermore, hyperinsulinemia activates c-Jun amino-terminal kinase 1 (JNK1), increases free fatty acid (FFA) and reactive oxygen species (ROS), and increases the level of some inflammatory cytokines. In addition to that, various molecular biologic mechanisms such as deregulated NF-κB signaling, disorder in PI3K-AKT-PTEN pathway, defect in one-carbon metabolism, and dysfunction of microRNAs are involved in the NAFLD-mediated carcinogenesis. Finally, intestinal dysbiosis may also play a role in the pathogenesis of HCC. These pathogenic mechanisms will be discussed shortly in this review. (J Liver Cancer 2014;14:63-72)

First
Prev
Page of 1
Next
Last

Search